- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
Withdrawn
Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
Condition
Urological
1 April 2025
Published on 02 Jul 2018
Last Updated on 01 Apr 2025
Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prosthetic hyperplasia Guidance is outdated and has been withdrawn on 1 April 2025.
Treatments for benign prostatic hyperplasia (Withdrawn 1 Apr 2025) [PDF, 52 KB]